872 trials (keyword fallback)
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Carcinoma, Hepatocellular
Primary: Time to Progression-Blinded Independent Central Review (BICR) Assessment — 5.6; 4.1 Months — p=0.7382
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 9.17; 7.62 months — p=0.1391
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Advanced or Metastatic Hepatocellular Cancer · Advanced or Metastatic Ovarian Cancer · Metastatic Renal Cell Cancer
Primary: Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All…
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Hepatocellular Cancer
Primary: Coagulation Zone Diameter-Short Axis — 36.0; 35.1 millimeters
Non-Small Cell Lung Cancer · Malignant Melanoma · Head and Neck Squamous Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg
Advanced Solid Tumors · Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 300 mg
Neuroendocrine Carcinoma
Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Hepatocellular Carcinoma · Liver Metastases · Cutaneous or Subcutaneous Lymph Node
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 2; 0; 1; 0 Participants